COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes
The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...
Medical Xpress on MSN16 天
Semaglutide (Ozempic) can be beneficial to people with type 1 diabetes
Semaglutide (known by its brandname Ozempic) has gained widespread attention for its weight loss benefits, but is officially approved for managing type 2 diabetes. While there is currently limited dat ...
Longview News-Journal17 天
Semaglutide (Ozempic) can be beneficial to people with type 1 diabetes
Semaglutide (known by its brandname Ozempic) has gained widespread attention for its weight loss benefits, but is officially approved for managing type 2 diabetes. While there is currently ...